Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer

Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer

Antibodies targeting the receptor programmed death 1 on T cells have been approved for the treatment of lung cancer. Immune checkpoint inhibitors (ICIs) induce various immune-related adverse events. Life-threatening hematotoxicity can be provoked by ICI therapy. Although ICI-related endocrinopathy a...

Full description

Bibliographic Details
Main Authors: Hidenori Mori, Chizuru Sakai, Masamichi Iwai, Yuka Sasaki, Takenobu Gomyo, Sayaka Toyoshi, Daizo Kaito, Komei Yanase, Fumitaka Ito, Junki Endo, Norihiko Funaguchi, Yasushi Ohno, Shinya Minatoguchi
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:Respiratory Medicine Case Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2213007119300991

Internet

http://www.sciencedirect.com/science/article/pii/S2213007119300991

Similar Items